HOME >> MEDICINE >> NEWS
Earlier treatment of perinatal HIV associated with decreased HIV progression, better outcomes

In a study in the May 11 JAMA, earlier treatment of children with HIV infection with ART is associated with less HIV progression and improved survival rates.

Worldwide, approximately 2.5 million children are infected with HIV, and approximately 1,700 new perinatal infections occur daily, according to background information in the article. In the United States, more than 9,300 HIV-infected children younger than 13 years have progressed to AIDS as of December 2003. While the Pediatric AIDS Clinical Trials Group (PACTG) 076 regimen has reduced perinatal transmission by 67 percent, prenatal combination ART has further reduced transmission to 2 percent or less. However, the impact of treatment on progression of perinatal HIV infection remains poorly characterized at the population level. Perinatal HIV infection may progress in 2 patterns: early, with a typical onset of age 4 months, or late, with a typical onset of age 6 years.

David R. Berk, M.D., of the Stanford University School of Medicine, Stanford, Calif., and colleagues conducted a study to determine the progression of HIV, survival, and distribution of category C (the most severe of three categories, dependent on symptomatic conditions) diagnoses in a perinatal population-based sample during different eras in prevention and management and in relation to early institution of any ART therapy. The researchers examined the trends in early progression of perinatal HIV infection among 205 HIV-infected children in Northern California born between January 1, 1988, and December 31, 2001, and followed up through age 3 years.

The researchers found that of 205 children, 134 (65 percent) received ART and/or prophylactic treatment against Pneumocystis jiroveci pneumonia. By age 3 years, 81 (40 percent) progressed to a category C diagnosis, 41 (51 percent) of whom died. Untreated children were significantly more likely to progress to a category C diagnosis (62 percent [44/71] untreated vs. 28 pe
'"/>

Contact: Krista Conger
650-725-5371
JAMA and Archives Journals
10-May-2005


Page: 1 2 3

Related medicine news :

1. Earlier periodontal treatment leads to lower medical costs
2. Spot on treatment for acne
3. New treatment boosts muscle function in myasthenia gravis
4. New treatment effective in counteracting cocaine-induced symptoms
5. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
6. Preventive treatments in elderly people needs rethinking
7. Osteoporosis screening and treatment may be cost-effective for selected older men
8. Quality of treatment guidelines
9. Green tea holds promise as new treatment for inflammatory skin diseases
10. Many heart attack patients still not getting emergency clot-busting treatment
11. Electric fields have potential as a cancer treatment

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... CITY, UTAH (PRWEB) , ... April 28, 2017 ... ... as Account Manager for the North East region. Côté has 20+ years of ... consulting. Prior to Phytomer, Côté worked with an array of high-end cosmetic brands, ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... its 5th anniversary. SearchLight is the premier online modeling resource for fluorescence microscopists ... than 30,000 active users during last 5 years spanning the globe, SearchLight has ...
(Date:4/27/2017)... ... April 27, 2017 , ... Thinksport, the leaders in safe, ... award-winning sunscreen they’ve used the same scientific approach to solving smelly, sweaty athletes, ... the aisles that contain harmful chemicals that should be put nowhere near your ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... Offering the ... with an oil many times purer and more potent than the market has seen ... of Gstaad, Switzerland, as well as a patented chromatography process for extraction, to produce ...
(Date:4/26/2017)... ... April 26, 2017 , ... Journal of Oral Implantology ... severe consequences to overall dental health, including complications with speech, eating, and overcompensation of ... implants to replace lost teeth. As the number of tooth replacements increase, it is ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
(Date:4/20/2017)... , April 20, 2017 Research ... America Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, ... Segment Forecasts, 2014 - 2025" report to their offering. ... The Latin American ... 21.0 billion by 2025 Low drug registration cost ...
(Date:4/19/2017)...  IRIDEX Corporation (Nasdaq: IRIX ) today ... first quarter 2017 after the close of trading on ... host a corresponding conference call beginning at 2:30 p.m. ... in listening to the conference call may do so ... 326-3030 for international callers, using conference ID: 92158987.  A ...
Breaking Medicine Technology:
Cached News: